title: Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.
abstract: One hundred and forty-four evaluable patients with recurrent or metastatic renal cell carcinoma (RCC) were treated with vinblastine infusion (n = 35), L-alanosine (n = 36), acivicin (n = 27), or aminothiadiazole (n = 46). Observed objective response rates of 9%, 3%, 4%, and 2%, respectively indicate that noe of these agents has significant antineoplastic activity in recurrent or metastatic RCC. Multivariate analysis of survival data suggests that initial performance status, time from initial diagnosis to study entry, and the presence or absence of lung metastases are important prognostic factors for survival. After adjustment for these factors, treatment assignment was also seen to be of prognostic value. All four treatments were generally well tolerated. There were no reports of life-threatening or lethal toxicities; however, 37% of the patients experienced severe reactions to treatment, primarily myelosuppression, anemia, neuropathies, and mucositis.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Elson
authors.forename: L K
authors.initials: LK
authors.lastname: Kvols
authors.forename: S E
authors.initials: SE
authors.lastname: Vogl
authors.forename: D J
authors.initials: DJ
authors.lastname: Glover
authors.forename: R G
authors.initials: RG
authors.lastname: Hahn
authors.forename: D L
authors.initials: DL
authors.lastname: Trump
authors.forename: P P
authors.initials: PP
authors.lastname: Carbone
authors.forename: J D
authors.initials: JD
authors.lastname: Earle
authors.forename: T E
authors.initials: TE
authors.lastname: Davis
mesh_terms: D000328:Adult; D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010080:Oxazoles / Q000627:therapeutic use*; D013830:Thiadiazoles / Q000627:therapeutic use*; D014747:Vinblastine / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007555:Isoxazoles; D010080:Oxazoles; D013830:Thiadiazoles; C000082:alanosine; D014747:Vinblastine; C010852:2-amino-1,3,4-thiadiazole; C006303:acivicin; D000409:Alanine